Literature DB >> 12705850

Viral infection results in massive CD8+ T cell expansion and mortality in vaccinated perforin-deficient mice.

Vladimir P Badovinac1, Sara E Hamilton, John T Harty.   

Abstract

Perforin-mediated cytotoxicity is essential for clearance of primary LCMV infection. BALB/c-perforin-deficient (PKO) mice survived LCMV infection by deleting NP(118)-specific CD8(+) T cells whereas vaccination of PKO mice with Listeria expressing NP(118) generated a stable memory CD8(+) T cell population. However, >85% of vaccinated BALB/c-PKO mice died after LCMV infection. Mortality was associated with enormous expansion of NP(118)-specific CD8(+) T cells in both lymphoid and nonlymphoid tissues and aberrant CD8(+) T cell cytokine production. Depletion of CD8(+) T cells or treatment with anti-IFNgamma antibody rescued vaccinated mice from mortality. Thus, perforin was essential for resistance to secondary LCMV infection, and, in the absence of perforin, vaccination resulted in lethal disease mediated by dysregulated CD8(+) T cell expansion and cytokine production.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12705850     DOI: 10.1016/s1074-7613(03)00079-7

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  35 in total

1.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Critical role for perforin and Fas-dependent killing of dendritic cells in the control of inflammation.

Authors:  Min Chen; Kumar Felix; Jin Wang
Journal:  Blood       Date:  2011-10-31       Impact factor: 22.113

3.  Early establishment of diverse T cell receptor profiles for influenza-specific CD8(+)CD62L(hi) memory T cells.

Authors:  Katherine Kedzierska; Vanessa Venturi; Kenneth Field; Miles P Davenport; Stephen J Turner; Peter C Doherty
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

4.  Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo.

Authors:  Jianping Yang; Stephanie P Huck; Rebecca S McHugh; Ian F Hermans; Franca Ronchese
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-22       Impact factor: 11.205

5.  Memory CD8+ T cells protect dendritic cells from CTL killing.

Authors:  Payal B Watchmaker; Julie A Urban; Erik Berk; Yutaro Nakamura; Robbie B Mailliard; Simon C Watkins; S Marieke van Ham; Pawel Kalinski
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

6.  IFN-γ and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis.

Authors:  Stéphanie Humblet-Baron; Dean Franckaert; James Dooley; Fatima Ailal; Aziz Bousfiha; Caroline Deswarte; Carmen Oleaga-Quintas; Jean-Laurent Casanova; Jacinta Bustamante; Adrian Liston
Journal:  J Allergy Clin Immunol       Date:  2018-12-19       Impact factor: 10.793

7.  CD8 T Cell Memory Increases Immunopathology in the Perforin-Deficient Model of Hemophagocytic Lymphohistiocytosis Secondary to TNF-α.

Authors:  Matthew D Taylor; Thomas N Burn; E John Wherry; Edward M Behrens
Journal:  Immunohorizons       Date:  2018-02

8.  Perforin is a critical physiologic regulator of T-cell activation.

Authors:  Jennifer E Lykens; Catherine E Terrell; Erin E Zoller; Kimberly Risma; Michael B Jordan
Journal:  Blood       Date:  2011-05-23       Impact factor: 22.113

9.  Protection against polyoma virus-induced tumors is perforin-independent.

Authors:  Anthony M Byers; Annette Hadley; Aron E Lukacher
Journal:  Virology       Date:  2006-09-28       Impact factor: 3.616

10.  Population dynamics of naive and memory CD8 T cell responses after antigen stimulations in vivo.

Authors:  Matthew D Martin; Stephanie A Condotta; John T Harty; Vladimir P Badovinac
Journal:  J Immunol       Date:  2011-12-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.